@article{498f9e703c3e4e7b8fbbcb8f7eed2956,
title = "Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis",
author = "Srdan Verstovsek and Levine, {Ross L.} and Stein, {Brady L.}",
note = "Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation . Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation.Srdan Verstovsek, MD, PhD has research grants from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Cell Therapeutics, Inc.; Geron; Gilead Sciences, Inc.; lncyte Corporation; Infinity Pharmaceuticals, Inc.; Lilly Oncology; Novartis Pharmaceuticals Corporation; NS Pharma, Inc.; Promedior, Inc.; Roche; Seattle Genetics; YM Biosciences.Ross L. Levine, MD has a research grant from Incyte Corporation.",
year = "2014",
month = dec,
doi = "10.1016/j.clml.2014.08.002",
language = "English (US)",
volume = "14",
pages = "e229",
journal = "Clinical Lymphoma",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "6",
}
